Insulin therapy for type 2 diabetes mellitus

JAMA

Volumn 311, Issue 22, 2014, Pages 2315-2325

  Wallia, Amisha ^a   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN PEGLISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SHORT ACTING INSULIN; SULFONYLUREA;

DRUG DELIVERY DEVICE; DRUG FORMULATION; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; EDEMA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFUSION PUMP; INSULIN RESISTANCE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84902169529     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.5951     Document Type: Review

References (100)

1. National Diabetes Information Clearinghouse. National Diabetes Statistics 2011. http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed April 25, 2014.
2. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
4. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602-613.
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
6. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
7. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
8. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
9. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. (Pubitemid 351831357)
10. Duckworth W, Abraira C, Moritz T, et al VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
11. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care. 2014;37(suppl 1):S14-S80.
12. National Collaborating Center for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). London, England: National Institute for Health and Clinical Excellence; 2008. Clinical guideline 66. http://guidance.nice.org.uk/CG66. Accessed March 11, 2014.
13. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents. London, England: National Institute for Health and Clinical Excellence; 2011. Clinical guideline 87. http://guidance.nice.org.uk/CG87. Accessed March 11, 2014.
14. International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels, Belgium: International Diabetes Federation Clinical Guidelines Task Force; 2012. http://www.idf.org. Accessed March 11, 2014.
15. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154(8):554-559.
16. Riddle MC, Karl DM. Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care. 2012;35(10):2100-2107.
17. Nathan DM, Bayless M, Cleary P, et al; DCCT/EDIC Research Group. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes. 2013;62(12):3976-3986.
18. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-885. (Pubitemid 36929359)
19. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1c levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-2514.
20. Garber AJ. Methods to enhance delivery of prandial insulin and basal-prandial insulin. Diabetes Obes Metab. 2013;15(3)(suppl 1):11-17.
21. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7(2):188-199. (Pubitemid 14137203)
22. Borgoño CA, Zinman B. Insulins: past, present, and future. Endocrinol Metab Clin North Am. 2012;41(1):1-24.
23. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: ameta-analysis. CMAJ. 2009;180(4):385-397.
24. Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14(5):433-446.
25. Rys P, Pankiewicz O, Łach K, Kwaskowski A, Skrzekowska-Baran I, Malecki MT. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab. 2011;37(3):190-200.
26. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142-2148.
27. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614-1620. (Pubitemid 38697678)
28. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir vs insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;(7):CD006383.
29. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086. (Pubitemid 37339502)
30. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274. (Pubitemid 44125921)
31. van Avendonk MJP, Rutten GEHM. Insulin therapy in type 2 diabetes: what is the evidence? Diabetes Obes Metab. 2009;11(5):415-432.
32. Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab. 2010;12(9):772-779.
33. Jensen MG, Hansen M, Brock B, Rungby J. Differences between long-acting insulins for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2010;11(12):2027-2035.
34. Pandya N, DiGenio A, Gao L, Patel M. Efficacy and safety of insulin glargine compared to other interventions in younger and older adults: a pooled analysis of nine open-label, randomized controlled trials in patients with type 2 diabetes. Drugs Aging. 2013;30(6):429-438.
35. Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med. 2012;29(3):303-312.
36. Ridderstråle M, Jensen MM, Gjesing RP, Niskanen L. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden. J Med Econ. 2013;16(4):468-478.
37. Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260-265. (Pubitemid 40170923)
38. Holman RR, Thorne KI, Farmer AJ, et al; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716-1730. (Pubitemid 350005153)
39. 1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510-517.
40. Holman RR, Farmer AJ, Davies MJ, et al; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736-1747.
41. de la Peña A, Riddle M, Morrow LA, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin vs human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34(12):2496-2501.
42. Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6(2):412-420.
43. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408-416.
44. Yki-Järvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23(8):1130-1136. (Pubitemid 30616801)
45. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract. 2011;17(5):727-736.
46. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month "proof-of- concept" study. Diabetes Obes Metab. 2011;13(11):1020-1027.
47. Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract. 2011;17(3):395-403.
48. Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31(7):1305-1310.
49. Gillespie SJ, Kulkarni KD, Daly AE. Using carbohydrate counting in diabetes clinical practice. J Am Diet Assoc. 1998;98(8):897-905. (Pubitemid 28364315)
50. Chiesa G, Piscopo MA, Rigamonti A, et al. Insulin therapy and carbohydrate counting. Acta Biomed. 2005;76(suppl 3):44-48. (Pubitemid 351767162)
51. Harris SB, Yale J-F, Berard L, et al. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial. Diabetes Care. 2014;37(3):604-610.
52. Leahy JL. Insulin therapy in type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2012;41(1):119-144.
53. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443. (Pubitemid 44903747)
54. Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab. 2011;13(9):814-822.
55. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012;34(6):1247-1258, e22.
56. Yki-Järvinen H, Rosenstock J, Durán-Garcia S, et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Diabetes Care. 2013;36(12):3875-3881.
57. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103-112.
58. Li C-J, Li J, Zhang Q-M, et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol. 2012;11:142.
59. Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. PLoS One. 2009;4(7):e6112.
60. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34(3):222-234. (Pubitemid 15134779)
61. Umpierrez GE, Smiley D, Hermayer K, et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care. 2013;36(8):2169-2174.
62. Rubin DJ, Rybin D, Doros G, McDonnell ME. Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. Diabetes Care. 2011;34(8):1723-1728.
63. Baldwin D, Zander J, Munoz C, et al. A randomized trial of 2 weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35(10):1970-1974.
64. Arakawa M, Ebato C. Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy. Diabetes Metab Syndr. 2013;7(4):223-225.
65. Hohberg C, Pfützner A, Forst T, et al. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch study. Diabetes Obes Metab. 2009;11(5):464-471.
66. Okamoto T, Okamoto L, Lisanti MP, Akishita M. Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes. Geriatr Gerontol Int. 2008;8(4):218-226.
67. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27(5):1028-1032. (Pubitemid 38579760)
68. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008;31(10):1927-1932.
69. Li Y, XuW, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care. 2004;27(11):2597-2602.
70. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753-1760. (Pubitemid 351697950)
71. Rolla A. The pathophysiological basis for intensive insulin replacement. Int J Obes Relat Metab Disord. 2004;28(suppl 2):S3-S7. (Pubitemid 39389600)
72. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1(1):28-34.
73. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
74. Riddle MC, Ambrosius WT, Brillon DJ, et al; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1c and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33(5):983-990.
75. Seaquist ER, Miller ME, Bonds DE, et al ACCORD Investigators. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care. 2012;35(2):409-414.
76. Gerstein HC, Bosch J, Dagenais GR, et al; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328.
77. Malik S, Lopez V, Chen R, Wu W, Wong ND. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007;77(1):126-133. (Pubitemid 46590472)
78. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335-342. (Pubitemid 38101606)
79. Patrick AR, Fischer MA, Choudhry NK, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2014;29(2):320-327.
80. Polonsky W. Psychological insulin resistance: the patient perspective. Diabetes Educ. 2007;33(4)(suppl 7):241S-244S.
81. Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013;126(9)(suppl 1):S38-S48.
82. Peyrot M, Rubin RR, Lauritzen T, et al; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679. (Pubitemid 43951158)
83. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543-2545. (Pubitemid 41384310)
84. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(suppl 5A):27S-34S. (Pubitemid 40585813)
85. Polinski JM, Smith BF, Curtis BH, et al. Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ. 2013;39(1):53-65.
86. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872-1894.
87. Asche CV, Bode B, Busk AK, Nair SR. The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(1):47-57.
88. Branda ME, LeBlanc A, Shah ND, et al. Shared decision making for patients with type 2 diabetes: a randomized trial in primary care. BMC Health Serv Res. 2013;13:301.
89. Fisher L, Hessler D, Glasgow RE, et al. REDEEM: a pragmatic trial to reduce diabetes distress. Diabetes Care. 2013;36(9):2551-2558.
90. Safren SA, Gonzalez JS, Wexler DJ, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes. Diabetes Care. 2014;37(3):625-633.
91. Zinman B, Philis-Tsimikas A, Cariou B, et al; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec vs insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464-2471.
92. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOWVOLUME trial. Diabetes Care. 2013;36(9):2536-2542.
93. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, vs insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35(11):2140-2147.
94. Ahmann A, Szeinbach SL, Gill J, Traylor L, Garg SK. Comparing patient preferences and healthcare provider recommendations with the pen vs vial-and-syringe insulin delivery in patients with type 2 diabetes. Diabetes Technol Ther. 2014;16(2):76-83.
95. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29(6 pt 1):1294-1305. (Pubitemid 351172225)
96. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen vs vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract. 2011;17(6):845-852.
97. Anderson BJ, Redondo MJ. What can we learn from patient-reported outcomes of insulin pen devices? J Diabetes Sci Technol. 2011;5(6):1563-1571.
98. Reznik Y, Cohen O. Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes. Diabetes Care. 2013;36(2)(suppl 2):S219-S225.
99. Bloomgarden ZT. Aspects of insulin treatment. Diabetes Care. 2010;33(1):e1-e6.
100. Klonoff DC, Buckingham B, Christiansen JS, et al Endocrine Society. Continuous glucose monitoring: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(10):2968-2979.